Toll-Like Receptor 3 (TLR-3) Agonist - Pipeline Insight, 2021

Publisher Name :
Date: 10-Feb-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Toll-Like Receptor 3 (TLR-3) Agonist - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Toll-Like Receptor 3 (TLR-3) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Toll-Like Receptor 3 (TLR-3) Agonist Understanding

Toll-Like Receptor 3 (TLR-3) Agonist: Overview

TLR3 is a member of the toll-like receptor (TLR) family. It plays a fundamental role in pathogen recognition and activation of innate immunity. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. TLR3 agonist formulation are the most extensively tested as a single agent in humans with infectious diseases and cancers including glioblastoma, renal cell cancer, melanoma, leukemia, ovarian cancer, and breast cancer. In studies, TLR3 signaling is activated by a synthetic dsRNA agonist, polyriboinosinic: polyribocytidylic acid, a potent immune stimulant that has been shown to induce protective immunity against influenza, HBV, a few HIV strains and coronaviruses.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Toll-Like Receptor 3 (TLR-3) Agonist R&D. The therapies under development are focused on novel approaches for Toll-Like Receptor 3 (TLR-3) Agonist.

Toll-Like Receptor 3 (TLR-3) Agonist Emerging Drugs Chapters

This segment of the Toll-Like Receptor 3 (TLR-3) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Toll-Like Receptor 3 (TLR-3) Agonist Emerging Drugs

- Rintatolimod: AIM ImmunoTech

Rintatolimod is a synthetic derivative of inosinic acid with antiretroviral and immunomodulatory properties. Rintatolimod is a mismatched double stranded polymer of RNA. It is a restricted Toll-Like Receptor 3 (TLR3) agonist lacking activation of other primary cellular inducers of innate immunity (e.g. cytosolic helicases). Rintatolimod was granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer in December 2020.

- PrEP-001: PrEP Biopharm

PrEP-001 is a nasal powder, a proprietary formulation of polyriboinosinic and polyribocytidylic acid effectively that elicits a cellular innate immune response in nasal epithelium. It is in Phase 2 for the prevention of influenza, influenza-like-illness and the common cold. PrEP-001, triggers the innate immune system through the Rig-I, MDA5 and TLR3 receptors and is expected to provide a rapid, broad-spectrum prophylaxis against ~200 respiratory viruses.

Further product details are provided in the report……..

Toll-Like Receptor 3 (TLR-3) Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Toll-Like Receptor 3 (TLR-3) Agonist drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players working on Toll-Like Receptor 3 (TLR-3) Agonist

There are approx. 5+ key companies which are developing the Toll-Like Receptor 3 (TLR-3) Agonist. The companies which have their Toll-Like Receptor 3 (TLR-3) Agonist drug candidates in the most advanced stage, i.e. Phase II include, AIM ImmunoTech.

- Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

- Late-stage products (Phase III and

- Mid-stage products (Phase II and

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Toll-Like Receptor 3 (TLR-3) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Infusion

- Intradermal

- Intramuscular

- Intranasal

- Intravaginal

- Oral

- Parenteral

- Subcutaneous

- Topical

- Molecule Type

Products have been categorized under various Molecule types such as

- Vaccines

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Toll-Like Receptor 3 (TLR-3) Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Toll-Like Receptor 3 (TLR-3) Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Toll-Like Receptor 3 (TLR-3) Agonist drugs.

Toll-Like Receptor 3 (TLR-3) Agonist Report Insights

- Toll-Like Receptor 3 (TLR-3) Agonist Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Toll-Like Receptor 3 (TLR-3) Agonist Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing Toll-Like Receptor 3 (TLR-3) Agonist drugs?

- How many Toll-Like Receptor 3 (TLR-3) Agonist drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for Toll-Like Receptor 3 (TLR-3) Agonist?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Toll-Like Receptor 3 (TLR-3) Agonist therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Toll-Like Receptor 3 (TLR-3) Agonist and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- AIM ImmunoTech

- PrEP Biopharm

- Oncovir

- Bioncotech Therapeutics

Key Products

- Rintatolimod

- PrEP-001

- Poly ICLC

- BO-112

Toll-Like Receptor 3 (TLR-3) Agonist - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Toll-Like Receptor 3 (TLR-3) Agonist: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Toll-Like Receptor 3 (TLR-3) Agonist - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Toll-Like Receptor 3 (TLR-3) Agonist companies' collaborations, Licensing, Acquisition -Deal Value Trends
Toll-Like Receptor 3 (TLR-3) Agonist Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Rintatolimod: AIM ImmunoTech
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Toll-Like Receptor 3 (TLR-3) Agonist Key Companies
Toll-Like Receptor 3 (TLR-3) Agonist Key Products
Toll-Like Receptor 3 (TLR-3) Agonist- Unmet Needs
Toll-Like Receptor 3 (TLR-3) Agonist- Market Drivers and Barriers
Toll-Like Receptor 3 (TLR-3) Agonist- Future Perspectives and Conclusion
Toll-Like Receptor 3 (TLR-3) Agonist Analyst Views
Toll-Like Receptor 3 (TLR-3) Agonist Key Companies
Appendix

List of Tables

Table 1 Total Products for Toll-Like Receptor 3 (TLR-3) Agonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Toll-Like Receptor 3 (TLR-3) Agonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Insights and Forecast to 2028
    Published: 19-Jan-2022        Price: US 4900 Onwards        Pages: 125
    Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Cell......
  • Global Cancer Immunomodulator Market Insights and Forecast to 2028
    Published: 14-Jan-2022        Price: US 4900 Onwards        Pages: 92
    Cancer Immunomodulator market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Cancer Immunomodulator market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Method of Use:CoQ10 - Method of Use:Levamisole Coating Agent Segment by Applica......
  • Global Circulating Tumor Cells Market Insights and Forecast to 2028
    Published: 13-Jan-2022        Price: US 4900 Onwards        Pages: 111
    Circulating Tumor Cells market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Circulating Tumor Cells market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - CTC Enrichment - CTC Detection - CTC Analysis Segme......
  • Global Immuno-Oncology Market Insights and Forecast to 2028
    Published: 11-Jan-2022        Price: US 4900 Onwards        Pages: 92
    Immuno-Oncology market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Immuno-Oncology market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Immune Checkpoint Inhibitors - Cytokine-Based Immunotherapy - Cancer Vaccines......
  • Global Circulating Tumor Cells Market Size, Status and Forecast 2022
    Published: 10-Jan-2022        Price: US 3900 Onwards        Pages: 120
    Circulating Tumor Cells market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Circulating Tumor Cells market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. Segment by Type - CTC Enrichment - CTC Detection......
  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size, Status and Forecast 2022
    Published: 10-Jan-2022        Price: US 3900 Onwards        Pages: 129
    Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. ......
  • Global Immuno-Oncology Market Growth (Status and Outlook) 2022-2028
    Published: 06-Jan-2022        Price: US 3660 Onwards        Pages: 87
    As the global economy mends, the 2021 growth of Immuno-Oncology will have significant change from previous year. According to our (LP Information) latest study, the global Immuno-Oncology market size is USD million in 2022 from USD 42700 million in 2021, with a change of % between 2021 and 2022. The global Immuno-Oncology market size will reach USD 116780 million in 2028, growing at a CAGR of 15.5% over the analysis period. The United States Immuno-Oncology market is expected at v......
  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2022-2028
    Published: 06-Jan-2022        Price: US 3660 Onwards        Pages: 121
    As the global economy mends, the 2021 growth of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) will have significant change from previous year. According to our (LP Information) latest study, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size is USD million in 2022 from USD 14070 million in 2021, with a change of % between 2021 and 2022. The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size will reach USD 57240 million in ......
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) - Drugs in Development, 2021
    Published: 30-Dec-2021        Price: US 2500 Onwards        Pages: 4011
    Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) - Drugs in Development, 2021 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drugs In Development, 2021, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape. Acute myelocytic leukemia (AML), also known as acute myel......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs